Telomir Pharmaceuticals (TELO) to Release Quarterly Earnings on Tuesday

Telomir Pharmaceuticals (NASDAQ:TELO) will likely be releasing its results before the market opens on Tuesday, February 3rd. Analysts expect Telomir Pharmaceuticals to post earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Monday, November 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Trading Down 6.6%

TELO stock opened at $1.14 on Monday. The company has a market cap of $39.19 million, a price-to-earnings ratio of -3.08 and a beta of -0.49. Telomir Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $5.40. The firm has a 50-day moving average of $1.36 and a two-hundred day moving average of $1.48.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TELO. Marshall Wace LLP acquired a new position in shares of Telomir Pharmaceuticals in the 2nd quarter valued at $95,000. Raymond James Financial Inc. raised its holdings in Telomir Pharmaceuticals by 4,101.9% in the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after buying an additional 73,547 shares during the period. Jane Street Group LLC purchased a new stake in Telomir Pharmaceuticals in the 2nd quarter valued at about $62,000. Qube Research & Technologies Ltd acquired a new position in Telomir Pharmaceuticals in the second quarter valued at about $33,000. Finally, Bank of America Corp DE boosted its stake in Telomir Pharmaceuticals by 283.9% during the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after buying an additional 10,880 shares during the period.

Analyst Ratings Changes

TELO has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday, January 22nd. Rodman & Renshaw assumed coverage on Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $15.00.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.